A multicenter, double-blind, randomized, placebo-controlled, phase II trial in patients with thyroid eye disease showed a significant response to teprotumumab vs placebo.1
Dr. Douglas concluded that the results confirmed teprotumumab to be highly effective in reducing proptosis, supporting a positive benefit/risk profile in the treatment of thyroid eye disease and apparent disease-modifying activity.
“Both the percentage of patients who responded and the magnitude of response pointed to excellent efficacy,” he added.